The dispute over the Medicare drug price negotiation program has moved from a war of words into the courtroom.

The U.S. Chamber of Commerce and the federal government on Friday presented oral arguments before U.S. District Judge Michael Newman in Dayton, Ohio. The program, which was established by the Inflation Reduction Act, aims to save $25 billion annually by 2031 through price negotiations for the drugs that are most costly to Medicare.

Attorney Jeffrey Bucholtz, representing the chamber, argued that the program violates drugmakers' due process rights by giving the government power to effectively dictate prices for their products. "There is a very, very high risk, maybe a guarantee, but certainly a very, very high risk, that this regime will result in prices that are unfair," he said.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.